No Data
Shanghai Haixin Group Co., Ltd. Third Quarter Report 2024
Shanghai Haixin Group Co., Ltd. 2024 Semi-annual Report
Summary of Shanghai Haixin Group Co., Ltd.'s 2024 semi-annual report
Shanghai Haixin Group (600851.SH) released its half-year performance, with a 34.98% decrease in revenue and a net income of 0.102 billion yuan.
Shanghai Haixin Group (600851.SH) released its 2024 interim report, and during the reporting period, the company achieved revenue...
Shanghai Haixin Group (600851.SH): Two pharmaceutical holding companies under it currently do not produce antiviral traditional chinese medicine.
Shanghai Haixin Group (600851.SH) stated on the investor interaction platform on August 20 that its two pharmaceutical holding companies under the company currently do not produce antiviral traditional Chinese medicine.
Shanghai Haixin Group (600851.SH): The application for participation in the development of Sutent capsules was recently completed by a subsidiary and included in the list of breakthrough therapeutic drugs published by the drug evaluation center.
On August 6th, Gelunhui reported that Shanghai Haixin Group (600851.SH) stated on the investor interaction platform that the application for Malay acid sunitinib capsules submitted by its holding company, Jiangsu Suzhong Traditional Chinese Medicine Group Co., Ltd., has recently been included in the public announcement of breakthrough therapeutic drugs by the Drug Evaluation Center of the National Medical Products Administration. At present, the drug is still in Phase II clinical trials and will not have a significant impact on the company's operations and performance. The development of new drugs has a long cycle, requires significant investment, and involves high risk, with many unpredictable factors and a high degree of uncertainty. We urge investors to make cautious decisions and be mindful of investment risks.
No Data
No Data